stockrowBioCryst Pharmaceuticals, Inc.
BCRX Healthcare Drug Manufacturers Specialty & Generic
BioCryst Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $874.8 million, up 94.1% from fiscal 2024.
- Revenue
- +13.1%
- EPS
- +150.0%
- Free cash flow
- −18.7%
- Total debt
- +15.2%
Quarter to September 2026, against a year earlier
Follow BCRX
Alert me
BioCryst Pharmaceuticals, Inc. (BCRX) Free cash flow
BioCryst Pharmaceuticals, Inc.'s free cash flow for fiscal 2025 was $345.5M, compared with −$53.1M in fiscal 2024. Over the twelve months to 30 September 2026 it was $366.4M. Over the past ten years it has ranged from −$163.2M (fiscal 2022) to $345.5M (fiscal 2025) — the current reading is the highest in ten years. Free cash flow has risen for 3 consecutive fiscal years. BioCryst Pharmaceuticals, Inc. ranks 10th of 84 Drug Manufacturers Specialty & Generic companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $345.5M | — |
| FY2024 | −$53.1M | — |
| FY2023 | −$97.3M | — |
| FY2022 | −$163.2M | — |
| FY2021 | −$144.5M | — |
| FY2020 | −$135.6M | — |
| FY2019 | −$89.9M | — |
| FY2018 | −$92.9M | — |
| FY2017 | −$41.5M | — |
| FY2016 | −$58.7M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $32.8M | (68.55%) |
| Jun 2026 | $104.1M | — |
| Mar 2026 | −$62.2M | — |
| Dec 2025 | $291.7M | 624.20% |
| 43 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| BCRX BioCryst Pharmaceuticals, Inc. | $366.4M |
| TRLV Trulieve Cannabis Corp. compare | $242.5M |
| PBH Prestige Consumer Healthcare Inc. compare | $214.2M |
| ANIP ANI Pharmaceuticals, Inc. compare | $205.3M |
| PRGO Perrigo Company plc compare | $168.2M |
| XERS Xeris Biopharma Holdings, Inc. compare | $73.6M |
| RGC Regencell Bioscience Holdings Limited compare | −$14.7M |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | −$171.8M |
| ALVO Alvotech compare | −$211.7M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on BCRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement